Definium Therapeutics (DFTX) Net Equity Issued and Repurchased (2021 - 2023)

Definium Therapeutics (DFTX) has reported Net Equity Issued and Repurchased for 3 consecutive years, with $2.6 million the latest figure, recorded in Q4 2023.

• In Q4 2023, Net Equity Issued and Repurchased rose 254.25% year-over-year to $2.6 million; the TTM figure through Sep 2025 stood at $2.6 million (down 62.98% YoY), while the FY2024 annual figure was $984000.0, down 86.93% from the prior year.
• Net Equity Issued and Repurchased eased to $2.6 million in Q4 2023 per DFTX's latest filing, from $3.1 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $82.1 million in Q1 2021 and bottomed at -$185000.0 in Q2 2021.
• Historically, Net Equity Issued and Repurchased has averaged $13.1 million across 3 years, with a median of $1.3 million in 2023.
• Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased soared 687600.0% — and 2023, when it plunged 88.73%.
• Definium Therapeutics' Net Equity Issued and Repurchased stood at -$4000.0 in 2021, then jumped by 18350.0% to $730000.0 in 2022, then surged by 254.25% to $2.6 million in 2023.
• Business Quant data shows DFTX's Net Equity Issued and Repurchased at $2.6 million in Q4 2023, $3.1 million in Q3 2023, and $1.3 million in Q2 2023.